IGF-1, IGFBP-1, and IGFBP-3 Polymorphisms Predict Circulating IGF Levels but Not Breast Cancer Risk: Findings from the Breast and Prostate Cancer Cohort Consortium (BPC3)
IGF-1 has been shown to promote proliferation of normal epithelial breast cells, and the IGF pathway has also been linked to mammary carcinogenesis in animal models. We comprehensively examined the association between common genetic variation in the IGF1, IGFBP1, and IGFBP3 genes in relation to circulating IGF-I and IGFBP-3 levels and breast cancer risk within the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). This analysis included 6,912 breast cancer cases and 8,891 matched controls (n = 6,410 for circulating IGF-I and 6,275 for circulating IGFBP-3 analyses) comprised primarily of Caucasian women drawn from six large cohorts. Linkage disequilibrium and haplotype patterns were characterized in the regions surrounding IGF1 and the genes coding for two of its binding proteins, IGFBP1 and IGFBP3. In total, thirty haplotype-tagging single nucleotide polymorphisms (htSNP) were selected to provide high coverage of common haplotypes; the haplotype structure was defined across four haplotype blocks for IGF1 and three for IGFBP1 and IGFBP3. Specific IGF1 SNPs individually accounted for up to 5% change in circulating IGF-I levels and individual IGFBP3 SNPs were associated up to 12% change in circulating IGFBP-3 levels, but no associations were observed between these polymorphisms and breast cancer risk. Logistic regression analyses found no associations between breast cancer and any htSNPs or haplotypes in IGF1, IGFBP1, or IGFBP3. No effect modification was observed in analyses stratified by menopausal status, family history of breast cancer, body mass index, or postmenopausal hormone therapy, or for analyses stratified by stage at diagnosis or hormone receptor status. In summary, the impact of genetic variation in IGF1 and IGFBP3 on circulating IGF levels does not appear to substantially influence breast cancer risk substantially among primarily Caucasian postmenopausal women.
References
[1]
Sachdev D, Yee D (2001) The IGF system and breast cancer. Endocrine Related Cancer 8: 197–209.
[2]
Wood TL, Yee D (2000) IGFs and IGFBPs in the normal mammary gland and in breast cancer. Journal of Mammary Gland Biology and Neoplasia 5: 1–5.
[3]
Baxter RC (1994) Insulin-like growth factor binding proteins in the human circulation: a review. Hormone Research 42: 140–144.
[4]
Burger AM, Leyland-Jones B, Banerjee K, Spyropoulos DD, Seth AK (2005) Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. European Journal of Cancer 41: 1515–1527.
[5]
Hadsell DL, Bonnette SG (2000) IGF and insulin action in the mammary gland: lessons from transgenic and knockout models. Journal of Mammary Gland Biology and Neoplasia 5: 19–30.
[6]
Fletcher O, Gibson L, Johnson N, Altmann DR, Holly JMP, et al. (2005) Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiology, Biomarkers, & Prevention 14: 2–19.
[7]
Allen NE, Roddam AW, Allen DS, Fentiman IS, dosSantosSilva I, et al. (2005) A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. British Journal of Cancer 92: 1283–1287.
[8]
Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, et al. (2006) Polymorphisms of genes coding for insulin-like growth factor I and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. British Journal of Cancer 94: 299–307.
[9]
Cheng I, Penney KL, Stram DO, LeMarchand L, Giorgi E, et al. (2006) Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: The Multiethnic Cohort. Cancer Epidemiology, Biomarkers, & Prevention 15: 1993–1997.
[10]
Johansson M, McKay JD, Wiklund F, Rinaldi S, Verheus M, et al. (2007) Implications for prostate cancer of insulin-like growth factor-I (IGF-I) genetic variation and circulating IGF-I levels. J Clin Endocrinol Metab 92: 4820–4826.
[11]
Setiawan VW, Cheng I, Stram DO, Penney KL, LeMarchand L, et al. (2006) IGF-I genetic variation and breast cancer: the Multiethnic Cohort. Cancer Epidemiology, Biomarkers, & Prevention 15: 172–174.
[12]
Verheus M, McKay JD, Kaaks R, Canzian F, Biessy C, et al. (2007) Common genetic variation in the IGF-1 gene, serum IGF-I levels and breast density. Breast Cancer Res Treat (epub ahead of print).
[13]
Hunter DJ, Riboli E, Haiman CA, Albanes D, Altshuler D, et al. (2005) A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nature Reviews Cancer 5: 977–985.
[14]
Calle EE, Rodriguez C, Jacobs EJ, Almon ML, Chao A, et al. (2002) The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer 94: 500–511.
[15]
Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, et al. (2002) European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 5: 1113–1124.
[16]
Colditz GA, Hankinson SE (2005) The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer 5: 388–396.
[17]
Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE (2000) Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med 9: 19–27.
[18]
Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, et al. (2000) A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 151: 346–357.
[19]
Hayes RB, Reding D, Kopp W, Subar AF, Bhat N, et al. (2000) Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 21: 349S–355S.
[20]
Cheng I, Stram DO, Penney KL, Pike M, LeMarchand L, et al. (2006) Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. Journal of the National Cancer Institute 98: 123–134.
[21]
Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, et al. (2002) The structure of haplotype blocks in the human genome. Science 296: 2225–2229.
[22]
Stram DO, Haiman CA, Hirschhorn JN, Altshuler D, Kolonel LN, et al. (2003) Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 55: 27–36.
[23]
Packer PB, Yeager M, Staats B, Welch R, Crenshaw A, et al. (2004) SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Research 32: D528–532.
[24]
DeLellis K, Ingles S, Kolonel L, McKean-Cowdin R, Henderson B, et al. (2003) IGF1 genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort. Br J Cancer 88: 277–282.
[25]
Rinaldi S, Peeters PH, Berrino F, Dossus L, Biessy C, et al. (2006) IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 13: 593–605.
[26]
Schernhammer ES, Holly JM, Pollak MN, Hankinson SE (2005) Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14: 699–704.
[27]
Zaykin D, Westfall P, Young S, Karnoub M, Wagner M, et al. (2002) Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Human Heredity 53: 79–91.
[28]
Feigelson HS, Cox DG, Cann HM, Wacholder S, Kaaks R, et al. (2006) Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohorts. Cancer Research 66: 2468–2475.
[29]
Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN (2003) Polymorphic variation at the -202 locus in IGFBP3: influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. International Journal of Cancer 107: 60–64.
[30]
Slattery ML, Sweeney C, Wolff R, Herrick J, Baumgartner K, et al. (2007) Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in Southwestern United States. Breast Cancer Research and Treatment 104: 197–209.
[31]
Wagner K, Hemminki K, Israelsson , Grzybowska E, Soderberg M, et al. (2005) Polymorphisms in the IGF-1 and IGFBP-3 promoter and the risk of breast cancer. Breast Cancer Research and Treatment 92: 133–140.
